| Hazard Information | Back Directory | [Description]
Ipilimumab is a CTLA-4 blocking antibody that was approved by the
U.S. FDA in March 2011 for the treatment of unresectable or metastatic
melanoma. Therefore, ipilimumab has an indirect effect on tumors that is
mediated through blockade of CTLA-4 negative signaling and
augmentation of T-cell activity. It is one of a handful of
immunostimulatory drugs (e.g., aldesleukin and interferon alfa-2b) now approved for cancer therapy. | [Originator]
Bristol-Myers Squibb (United States) | [Uses]
Treatment of
oncology disease and HIV infection. | [Brand name]
Yervoy | [Clinical Use]
Antineoplastic agent:
Treatment of advanced (unresectable or metastatic)
melanoma in adults who have received prior therapy | [Drug interactions]
Potentially hazardous interactions with other drugs
Live vaccines: risk of generalised infections - avoid. | [Metabolism]
Most likely removed by opsonisation via the
reticuloendothelial system when bound to T lymphocytes,
or by human antimurine antibody production. |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0.htm |
|